Anbio Biotechnology vs Trinity Biotech
NNNN and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NNNN and TRIB compare
Anbio Biotechnology grew revenue faster over the last twelve months (5.6% versus −28.9% for Trinity Biotech).
Anbio Biotechnology keeps more of each dollar of sales as profit, with a net margin of 74.1% compared with −85.4% at Trinity Biotech.
Anbio Biotechnology scores higher on the StockData Score (11 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NNNN | TRIB |
|---|---|---|
| Size and price | ||
| Share price | $3.82 | $6.10 |
| Change, 1 year | −83.0% | −77.4% |
| Change, 5 years | – | −97.9% |
| Beta (5Y) | 1.55 | 1.44 |
| Employees | 27 | 287 |
| StockData Score | ||
| Total score | 11 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 5 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 5.6% (better) | −28.9% |
| Revenue growth, 5Y average | – | −15.6% |
| Net income growth (TTM) | 170% | – |
| EPS growth (TTM) | 163% | – |
| Profitability | ||
| Gross margin | 87.2% (better) | 38.6% |
| Operating margin | 66.7% (better) | −36.1% |
| Net margin | 74.1% (better) | −85.4% |
| FCF margin | – | −13.7% |
| Return on equity | 27.0% | – |
| Return on invested capital | 48.7% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.7× |
| Current ratio | 344.31 (better) | 0.25 |
| Piotroski F-score | 5 (better) | 4 |
| Ownership | ||
| Held by institutions | – | 0.01% |
| Held by insiders | 0.00% | 51.7% |
| Short interest, % of float | 0.02% | – |
Go deeper
- NNNN stock overview
- NNNN income statement
- NNNN valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.